PRMT1 inhibitors and uses thereof
View Patent ↗Described herein are compounds of Formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds described herein are useful for inhibiting PRMT1 activity. Methods of using the compounds for treating PRMT1-mediated disorders are also described.
1. A pharmaceutical composition comprising a compound selected from the following, or a pharmaceutically acceptable salt thereof,
and a pharmaceutically acceptable excipient.
2. A kit or packaged pharmaceutical comprising a compound selected from the following, or a pharmaceutically acceptable salt thereof,
and instructions for use thereof.
3. A method of treating a disorder, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula I,
or a pharmaceutically acceptable salt thereof,
wherein
X is N, Z is NR 4 , and Y is CR 5 ; or
X is NR 4 , Z is N, and Y is CR 5 ; or
X is CR 5 , Z is NR 4 , and Y is N; or
X is CR 5 , Z is N, and Y is NR 4 ;
R 2 is hydrogen, halo, —CN, —NO 2 , optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted heteroaryl, —OR A , —N(R B ) 2 , —SR A , —C(═O)R A , —C(O)OR A , —C(O)SR A , —C(O)N(R B ) 2 , —C(O)N(R B )N(R B ) 2 , —OC(O)R A , —OC(O)N(R B ) 2 , NR B C(O)R A , —NR B C(O)N(R B ) 2 , —NR B C(O)N(R B )N(R B ) 2 , —NR B C(O)OR A , —SC(O)R A , —C(═NR B )R A , —C(═NNR B )R A , —C(═NOR A )R A , —C(═NR B )N(R B ) 2 , —NR B C(═NR B )R B , —C(═S)R A , —C(═S)N(R B ) 2 , NR B C(═S)R A , —S(O)R A , —OS(O) 2 R A , —SO 2 R A , —NR B SO 2 R A , or —SO 2 N(R B ) 2 , wherein R 2 is not —CF 3 or —CHF 2 ;
R 6 is hydrogen, halo, —CN, —NO 2 , optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted heteroaryl, —OR A , —N(R B ) 2 , —SR A , —C(═O)R A , —C(O)OR A , —C(O)SR A , —C(O)N(R B ) 2 , —C(O)N(R B )N(R B ) 2 , —OC(O)R A , —OC(O)N(R B ) 2 , NR B C(O)R A , —NR B C(O)N(R B ) 2 , —NR B C(O)N(R B )N(R B ) 2 , —NR B C(O)OR A , —SC(O)R A , —C(═NR B )R A , —C(═NNR B )R A , —C(═NOR A )R A , —C(═NR B )N(R B ) 2 , —NR B C(═NR B )R B , —C(═S)R A , —C(═S)N(R B ) 2 , NR B C(═S)R A , —S(O)R A , —OS(O) 2 R A , —SO 2 R A , —NR B SO 2 R A , or —SO 2 N(R B ) 2 , wherein R 6 is not —CF 3 or —CHF 2 ;
each R A is independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, an oxygen protecting group when attached to an oxygen atom, and a sulfur protecting group when attached to a sulfur atom;
each R B is independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl, and a nitrogen protecting group, or two R B groups are taken together with their intervening atoms to form an optionally substituted heterocyclic ring;
R 3 is hydrogen, C 1-4 alkyl, or C 3-4 cycloalkyl;
R 4 is hydrogen, optionally substituted C 1-6 alkyl, optionally substituted C 2-6 alkenyl, optionally substituted C 2-6 alkynyl, optionally substituted C 3-7 cycloalkyl, optionally substituted 4- to 7-membered heterocyclyl; or optionally substituted C 1-4 alkyl-Cy;
Cy is optionally substituted C 3-7 cycloalkyl, optionally substituted 4- to 7-membered heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl;
R 5 is hydrogen, halo, —CN, optionally substituted C 1-4 alkyl, or optionally substituted C 3-4 cycloalkyl;
R x is optionally substituted C 1-4 alkyl or optionally substituted C 3-4 cycloalkyl;
R y is NR B C(O)R A , —NR B SO 2 R A , or (CR z R z ) n C(O)N(R B ) 2 ;
each R z is independently hydrogen or fluoro; and
n is 0, 1, 2, 3, or 4.
4. The method of claim 3 , wherein the disorder is a proliferative disorder, a neurological disorder, a muscular dystrophy, an autoimmune disorder, a vascular disorder, or a metabolic disorder.
5. The method of claim 4 , wherein the disorder is cancer.
6. The method of claim 4 , wherein the disorder is amyotrophic lateral sclerosis.
7. The method of claim 3 , wherein R y is —NHC(O)R A , —NHSO 2 R A , or —CH 2 C(O)N(R B ) 2 .
8. The method of claim 3 , wherein the compound is of Formula (II) or (III):
or a pharmaceutically acceptable salt thereof.
9. The method of claim 3 , wherein the compound is of Formula (IV) or (V):
or a pharmaceutically acceptable salt thereof.
10. The method of claim 3 , wherein R 2 is hydrogen, —OR A , halo, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclic, or —CN.
11. The method of claim 3 , wherein R 6 is hydrogen, —OR A , halo, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclic, or —CN.
12. The method of claim 3 , wherein R 3 is hydrogen or C 1-4 alkyl.
13. The method of claim 3 , wherein R 3 is hydrogen, methyl, ethyl, propyl, butyl, cyclopropyl, or cyclobutyl.
14. The method of claim 3 , wherein R 4 is hydrogen or optionally substituted C 1-6 alkyl.
15. The method of claim 3 , wherein R 5 is hydrogen or optionally substituted C 1-4 alkyl.
16. The method of claim 3 , wherein R x is optionally substituted C 1-4 alkyl.
17. The method of claim 3 , wherein R x is methyl, ethyl, propyl, butyl, isopropyl, hydroxyethyl, methoxyethyl, cyclopropyl, or cyclobutyl.
18. The method of claim 3 , wherein the compound is selected from the group consisting of:
and pharmaceutically acceptable salts thereof.